Together, the comparison of APL vs. AML2 revealed a diverse expression of well-known differentiation marker molecules, such as CD11b, CD13, CD14, CD15, and CD24, whereas fewer surface molecules were differentially expressed between APL and AML1. This evidence concerns the gene RUNX1 and acute promyelocytic leukemia.